Avalanche eyes $640m windfall in Regeneron deal
This article was originally published in Scrip
Executive Summary
Cash is piling on the mountaintop for Avalanche Biotechnologies, which negotiated a commitment for up to $640m in upfront and milestone fees plus royalties from Regeneron Pharmaceuticals in a gene therapy collaboration for ophthalmic diseases.